The need for rigorous evidence on medication use in preterm infants: Is it time for a neonatal rule?

JAMA

Volumn 308, Issue 14, 2012, Pages 1435-1436

  Davis, Jonathan M ^a   Connor, Edward M ^b   Wood, Alastair J J ^c,d  

^a TUFTS MEDICAL CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c Symphony Capital LLC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; DRUG;

APNEA; CEREBRAL PALSY; CHILD HEALTH; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; INFANT MORTALITY; LONG TERM CARE; LUNG DYSPLASIA; MALPRACTICE; MATERNAL WELFARE; MORBIDITY; NATIONAL HEALTH ORGANIZATION; NEONATOLOGY; NEWBORN INTENSIVE CARE; PREMATURITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; TREATMENT RESPONSE;

EID: 84867165202     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.12883     Document Type: Short Survey

References (8)

1. Institute of Medicine of the National Academies. Preterm birth: causes, consequences, and prevention. http://www.iom.edu/Reports/2006/Preterm-Birth- Causes-Consequences-and-Prevention.aspx. Accessibility verified September 14, 2012.
2. Kumar P, Walker JK, Hurt KM, et al. Medication use in the neonatal intensive care unit. J Pediatr. 2008;152(3):412-415.
3. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics. 2002;110(5):e53-e58.
4. US Food and Drug Administration. New pediatric labeling information database. http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd= labelingdatabase. Accessibility verified September 14, 2012.
5. US Government Accountability Office. Pediatric research: products studied under two related laws, but improved tracking needed by FDA. http://www.gao.gov/assets/320/319073.pdf. Accessibility verified September 14, 2012.
6. Schmidt B, Anderson PJ, Doyle LW, et al; Caffeine for Apnea of Prematurity (CAP) Trial Investigators. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307(3):275-282.
7. Cohen-Wolkowiez M, Ouellet D, Smith PB, et al. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother. 2012;56(4):1828-1837.
8. Institute of Medicine of the National Academies. Safe and effective medicines for children: pediatric studies conducted under BPCA and PREA. http://www.iom.edu/Reports/2012/Safe-and-Effective-Medicines-for-Children.aspx. Accessibility verified September 14, 2012.